Loading...

Spyre Therapeutics, Inc.

SYRE•NASDAQ
Healthcare
Biotechnology
$71.01
$1.88(2.72%)
U.S. Market opens in 3h 5m

Spyre Therapeutics, Inc. (SYRE) Stock Overview

Explore Spyre Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

Z

Key Financials

Market Cap4.3B
P/E Ratio-139.29
EPS (TTM)$-1.98
ROE-0.31%
Fundamental Analysis

AI Price Forecasts

1 Month$34.06
3 Months$39.76
1 Year Target$32.96

SYRE Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Spyre Therapeutics, Inc. (SYRE) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 63.48, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $32.96.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -139.29 and a market capitalization of 4.3B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
2.62%
5-Day Change
-1.92%
1-Month Change
44.83%
3-Month Change
115.36%
6-Month Change
210.46%
Year-to-Date (YTD) Change
116.54%
1-Year Change
403.48%
3-Year Change
1673.50%
5-Year Change
-61.39%
All-Time (Max) Change
-70.96%

Contact Information

https://www.spyre.com
617 651 5940
221 Crescent Street, Waltham, MA, 02453

Company Facts

73 Employees
IPO DateApr 7, 2016
CountryUS
Actively Trading

Frequently Asked Questions